Atopic Dermatitis | Emerging Therapies | Eucrisa | USis a three-wave series that tracks the introduction of Pfizer’s Eucrisa for the treatment of AD. The series is based on primary research data collected at 1, 6, and 12 months post-commercial launch from surveys of U.S. dermatologists. Along with awareness of, sources of familiarity with, and perceptions related to Eucrisa, the research assesses trial, adoption, and usage, including anticipated future trends, of Eucrisa. We also explore Pfizer’s promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other previously launched immune agents.

What you will learn in this content:

  • What is U.S. dermatologists' awareness of and familiarity with Eucrisa, and what are their perceptions of this product?
  • Among prescribers, for which patients are they prescribing Eucrisa, what are the reasons for prescribing, and how satisfied are they with Eucrisa?
  • What are the promotional messages and activities that Pfizer is employing in support of the Eucrisa launch?
  • How do prescribers and nonprescribers compare across key metrics?
  • How is the trial and adoption of Eucrisa tracking compared with other recent product launches in the AD market?

Methodology: ~75-100 U.S. dermatologists complete a 30-minute online quantitative survey with several open-ended questions for qualitative feedback.

Key drugs: Eucrisa

Key companies: Pfizer

Related reports: Atopic Dermatitis Disease Landscape and Forecast, Atopic Dermatitis Unmet Need, Access and Reimbursement – Atopic Dermatitis (US), Access and Reimbursement – Atopic Dermatitis (EU)

Table of contents

  • Atopic Dermatitis/Atopic Eczema - Emerging Therapies - Eucrisa Launch Tracking Wave 1 (US)

Author(s): Emily Schriner, MPH

Emily is an Business Insights Analyst with the Immune and Inflammatory Disorders team at Decision Resources Group. She has authored several content pieces for immune market research reports and keeps the team up-to-date on the immune markets through research on patent life, pricing, and pipeline information.

Emily earned her Master of Public Health in Nutrition at West Chester University, focusing on research, analysis, and program development. She completed an internship at Nemours Health Network in Wilmington, Delaware where she did nutrition education development and primary research on program evaluation before initially joining DRG as a data analyst on the Research Analytics Team.

Related Reports

Atopic Dermatitis/Atopic Eczema - Landscape & Forecast - Disease Landscape & Forecast

Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema; the main goals of treatment are to protect the skin barrier, redu...

View Details

Atopic Dermatitis/Atopic Eczema - Unmet Need - Detailed, Expanded Analysis - Moderate To Severe (US/EU)

The moderate to severe atopic dermatitis (AD) market is at the beginning of a revolution with the recent approval of Sanofi/Regeneron’s first-in-class b...

View Details